Chengdu Olymvax Biopharmaceuticals Future Growth
Future criteria checks 5/6
Chengdu Olymvax Biopharmaceuticals is forecast to grow earnings and revenue by 76.1% and 21.7% per annum respectively. EPS is expected to grow by 75.6% per annum. Return on equity is forecast to be 10.5% in 3 years.
Key information
76.1%
Earnings growth rate
75.6%
EPS growth rate
| Biotechs earnings growth | 43.4% |
| Revenue growth rate | 21.7% |
| Future return on equity | 10.5% |
| Analyst coverage | Low |
| Last updated | 28 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected
Oct 09
We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt
Sep 30What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You
Jun 24Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?
May 28Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Apr 18These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 885 | 126 | 61 | 141 | 2 |
| 12/31/2025 | 728 | 81 | -27 | 54 | 2 |
| 12/31/2024 | 608 | 53 | -7 | 97 | 2 |
| 9/30/2024 | 530 | -9 | -257 | -7 | N/A |
| 6/30/2024 | 489 | -39 | -217 | 7 | N/A |
| 3/31/2024 | 500 | -12 | -175 | 12 | N/A |
| 12/31/2023 | 496 | 18 | -126 | 44 | N/A |
| 9/30/2023 | 529 | 17 | -95 | 93 | N/A |
| 6/30/2023 | 548 | 24 | -205 | -11 | N/A |
| 3/31/2023 | 561 | 37 | -206 | -15 | N/A |
| 12/31/2022 | 547 | 27 | -225 | -25 | N/A |
| 9/30/2022 | 573 | 70 | -191 | -98 | N/A |
| 6/30/2022 | 551 | 97 | -95 | 13 | N/A |
| 3/31/2022 | 477 | 81 | -68 | 17 | N/A |
| 12/31/2021 | 487 | 108 | -30 | 40 | N/A |
| 9/30/2021 | 405 | 78 | -22 | 44 | N/A |
| 6/30/2021 | 378 | 65 | -18 | 21 | N/A |
| 3/31/2021 | 328 | 50 | -38 | 4 | N/A |
| 12/31/2020 | 320 | 36 | -18 | 21 | N/A |
| 12/31/2019 | 179 | -31 | -71 | -42 | N/A |
| 12/31/2018 | 76 | -19 | -35 | -17 | N/A |
| 6/30/2018 | 63 | 14 | N/A | -14 | N/A |
| 3/31/2018 | 54 | 7 | N/A | -8 | N/A |
| 12/31/2017 | 45 | 1 | N/A | -2 | N/A |
| 9/30/2017 | 26 | -23 | N/A | -21 | N/A |
| 6/30/2017 | 7 | -48 | N/A | -40 | N/A |
| 3/31/2017 | 4 | -52 | N/A | -41 | N/A |
| 12/31/2016 | 0 | -56 | N/A | -43 | N/A |
| 9/30/2016 | 0 | -51 | N/A | -37 | N/A |
| 6/30/2016 | 0 | -47 | N/A | -32 | N/A |
| 3/31/2016 | 0 | -50 | N/A | -29 | N/A |
| 12/31/2015 | 0 | -52 | N/A | -27 | N/A |
| 12/31/2014 | 0 | -30 | N/A | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688319 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: 688319 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688319 is expected to become profitable in the next 3 years.
Revenue vs Market: 688319's revenue (21.7% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 688319's revenue (21.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688319's Return on Equity is forecast to be low in 3 years time (10.5%).